282 related articles for article (PubMed ID: 1397746)
1. Appropriate acid suppression for the management of gastro-oesophageal reflux disease.
Bell NJ; Burget D; Howden CW; Wilkinson J; Hunt RH
Digestion; 1992; 51 Suppl 1():59-67. PubMed ID: 1397746
[TBL] [Abstract][Full Text] [Related]
2. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
Monés J
Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
[TBL] [Abstract][Full Text] [Related]
5. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
7. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
Gardner JD; Sloan S; Miner PB; Robinson M
Aliment Pharmacol Ther; 2003 Apr; 17(7):945-53. PubMed ID: 12656697
[TBL] [Abstract][Full Text] [Related]
8. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
9. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
Gardner JD; Rodriguez-Stanley S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2002 Oct; 16(10):1819-29. PubMed ID: 12269977
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.
Orr WC; Harnish MJ
Aliment Pharmacol Ther; 2003 Jun; 17(12):1553-8. PubMed ID: 12823159
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis.
Pouderoux P; Kahrilas PJ
Aliment Pharmacol Ther; 1995 Dec; 9(6):661-6. PubMed ID: 8824654
[TBL] [Abstract][Full Text] [Related]
12. Nocturnal gastric acidity pattern in gastro-oesophageal reflux disease with or without oesophagitis.
Sozzi M; Valentini M; Poletti M; Bertolissi E; Serraino D; Bovero E; De Iaco F
Ital J Gastroenterol; 1995; 27(8):413-8. PubMed ID: 8775466
[TBL] [Abstract][Full Text] [Related]
13. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
Lundell L
Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
[TBL] [Abstract][Full Text] [Related]
14. Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms.
Salvatore S; Hauser B; Salvatoni A; Vandenplas Y
Acta Paediatr; 2006 Feb; 95(2):176-81. PubMed ID: 16449023
[TBL] [Abstract][Full Text] [Related]
15. Impaired egress rather than increased access: an important independent predictor of erosive oesophagitis.
Jones MP; Sloan SS; Jovanovic B; Kahrilas PJ
Neurogastroenterol Motil; 2002 Dec; 14(6):625-31. PubMed ID: 12464084
[TBL] [Abstract][Full Text] [Related]
16. Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease.
Katz PO
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():3-11. PubMed ID: 16483265
[TBL] [Abstract][Full Text] [Related]
17. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.
Bell NJ; Hunt RH
Gut; 1992 Jan; 33(1):118-24. PubMed ID: 1346769
[TBL] [Abstract][Full Text] [Related]
18. Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.
Domínguez-Muñoz JE; Sobrino M
Drugs; 2005; 65 Suppl 1():43-50. PubMed ID: 16335857
[TBL] [Abstract][Full Text] [Related]
19. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease.
Hunt RH
Aliment Pharmacol Ther; 1995; 9 Suppl 1():3-7. PubMed ID: 7495939
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.
Ciccaglione AF; Marzio L
Gut; 2003 Apr; 52(4):464-70. PubMed ID: 12631652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
